<DOC>
	<DOCNO>NCT02991144</DOCNO>
	<brief_summary>A Phase 1/2 , open-label dose-finding safety study single ascending dos DTX301 adult late-onset OTC Deficiency</brief_summary>
	<brief_title>Safety Dose-Finding Study DTX301 ( scAAV8OTC ) Adults With Late-Onset OTC Deficiency</brief_title>
	<detailed_description>This Phase 1/2 , open-label , single arm , multicenter , safety dose find study DTX301 adult late-onset OTC deficiency . The primary objective study determine safety single IV dose DTX301 . A key secondary objective study identify optimal biological dose ( OBD ) DTX301 . Eligible subject receive single IV infusion DTX301 . Dose escalation conduct accord model us collect data predict safety profile dose order determine OBD . The decision proceed next dose cohort make data monitoring committee ( DMC ) evaluate safety data subject dose cohort . Subjects follow 52 week dose . After completion study , subject ask enroll 4-year extension study evaluate long term ( total 5 year ) safety efficacy DTX301 .</detailed_description>
	<mesh_term>Ornithine Carbamoyltransferase Deficiency Disease</mesh_term>
	<criteria>1 . Males females ≥18 year age document diagnosis late onset ( define first manifestation sign symptom ≥1 month age ) OTC deficiency , confirm via enzymatic , biochemical , molecular test 2 . Documented history ≥1 symptomatic hyperammonemia event ammonia ≥100 µmol/L . 3 . Subject 's OTC deficiency stable evidence either ) clinical symptom hyperammonemia OR b ) ammonia level &lt; 100 µmol/L within 4 week period precede Screening visit . 4 . On stable dose ammonia scavenger therapy ≥4 week . 5 . Males females childbearing potential must willing use effective contraception time administration gene transfer 52 week 1 . Screening Baseline ( Day 0 ) ammonia level ≥100 µmol/L sign symptom indicative hyperammonemia 4week period precede Day 0 2 . Liver transplant , include hepatocyte cell therapy/transplant . 3 . History liver disease 4 . Serum creatinine &gt; 2.0 mg/dL . 5 . Participation another investigational medicine study ( include another gene transfer trial ) within 3 month Screening 6 . History malignancy subject receive treatment past 2 year except prostate cancer treat watchful wait surgically remove non melanoma skin cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Gene Transfer</keyword>
	<keyword>OTC Deficiency</keyword>
	<keyword>Urea Cycle Disorder</keyword>
</DOC>